UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.